Patients benefit from advocating for themselves

When discussing the pros and cons of new drugs, new treatments, new studies or any new medical development with government regulators, people with different relationships to the health concern at hand often make up an advocacy groupincluding doctors, healthcare administrators, researchers, governmental representatives and patient caretakers and family members.

Increasingly, says the Wall Street Journal, those groups include patients themselves.

Some of those patients are living longer, thanks to previous advocacy on their behalf, and are able and want to make their own voices heard in those conversations.

Those patient voices can be making different points than those of their parents or caretakers. According to one parent advocate, patients sometimes focus on advocating for accessibility rights, while their parents just want them to stay safe.

Check out the Wall Street Journal to see how these groups are taking different approaches to including patients themselves in patient advocacy groups and how issues championed by patients themselves could change the healthcare landscape. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.